Elias Fattal is a full professor in Drug Delivery Science at the University of Paris-Sud in Châtenay-Malabry, France and has been President of APGI from 2003 to 2010. He received his Pharmacy Degree (1983) and Ph.D. (1990) from the University of Paris-Sud and followed an internship in Hospital Pharmacy at the University of Lille (1984-1986). After visiting the Department of Pharmaceutical Chemistry at the University of California, San Francisco for a post-doctoral position (1990-1991), he became Associate Professor (1992) and full Professor at the University of Paris-Sud (2000). He has been the head of the Institut Galien Paris-Sud (2010-2019). Over the past 25 years, he has made fundamental and applied contributions to the fields of drug delivery using nanotechnologies for targeted or local delivery of drugs and nucleic acids. He has been recently focusing on lung nanotoxicity. He has issued 14 patent families. Several of his inventions have been licensed to the pharmaceutical industry. He has been involved in the development of an adjuvant to antibiotics able to reduce resistance by adsorbing residual colonic antibiotics (clinical phase II). One of his patents led to Calixarene® Cevidra, a cream for the treatment of external actinide contamination. He has contributed to around 300 publications and book chapters. Prof. Fattal has received the Pharmaceutical Sciences World Congress (PSWC) Research Achievement (2007), the Controlled Release Society fellow Award (2016), was awarded in 2016 by the French Academy of Sciences for his research at the interface of chemistry and biology and more recently in 2018 received the Maurice-Marie Janot Award. He serves on the editorial board of several scientific journals.